2026 340B Program Update – 340B Rebate Model RFI Comments Due and Manufacturers Continue Restricting 340B Pricing

Why It Matters

The combined regulatory and manufacturer pressures threaten the cost‑savings that 340B provides, potentially eroding margins for safety‑net providers and reshaping the program’s financial sustainability.

Key Takeaways

• HRSA RFI comment deadline moved to April 20, 2026
• Eli Lilly and Novo Nordisk require 45‑day dispensing data submissions
• New rules raise admin costs and threaten 340B cash flow
• Providers must track pricing denials and ready ADR filings
• Detailed RFI feedback can influence future rebate‑model design

Pulse Analysis

The 340B drug pricing program, a cornerstone of safety‑net hospital financing, is at a crossroads as HRSA seeks stakeholder input on a proposed rebate‑model pilot. While the original deadline passed, the agency extended it to April 20, 2026, signaling a willingness to consider industry concerns. Commenters are expected to detail how a rebate structure would amplify compliance burdens, disrupt cash flow, and diverge from the statutory discount framework. By articulating these challenges, providers can shape policy outcomes that preserve the program’s original intent.

Concurrently, two major manufacturers—Eli Lilly and Novo Nordisk—have rolled out strict data‑submission mandates, requiring covered entities to report dispensing information within 45 days of each transaction. Failure to comply can result in the suspension of 340B pricing, directly affecting drug acquisition costs. The new rules impose significant operational strain, as pharmacies must upgrade reporting systems and allocate staff to manage the influx of data. This heightened scrutiny also creates a fertile ground for pricing denials, prompting many entities to anticipate a surge in Administrative Dispute Resolution (ADR) filings.

For providers, the immediate priority is two‑fold: submit comprehensive, evidence‑based comments to HRSA and establish robust monitoring mechanisms for pricing denials. Documenting lost discounts, estimating associated administrative expenses, and preparing ADR templates will streamline future dispute processes. Engaging manufacturers in good‑faith dialogue can also mitigate abrupt pricing interruptions. Ultimately, proactive advocacy combined with meticulous data management will be essential to safeguard the financial health of 340B participants amid evolving regulatory and commercial pressures.